NYBC Blood Group Genomics

NYBC’s Genomics Laboratory provides two DNA-based typing services: 

  1. Testing for RBC antigens
  2. Testing for platelet and neutrophil antigens 

Under the guidance of Laboratory Manager Sunitha Vege, MS, the laboratory uses methods that include DNA array, PCR-RFLP, AS-PCR and gene specific amplification and sequencing, mRNA isolation, and cDNA sequencing when the situation arises. All results are reviewed in the context of serology and genomics at multiple levels to ensure that you receive information and clinical guidance for every situation.

Genomics Testing Services 

  • Red cell phenotyping based on genetics
  • ABO genotyping and subgroup investigation
  • RHD genotyping, including weak D, partial D, and zygosity
  • RHCE genotyping, including partial, altered, or silenced Cc or Ee
  • Null phenotypes in any blood group system
  • New antigen investigation
  • Platelet (HPA) typing, including HPA 1 through 9, 11, and 15
  • Neutrophil (HNA) typing (HNA-3a/b) 

DNA Testing Indications

  • Obtain extensive antigen profile on:
    • Recently transfused patients
    • Patients with positive direct antiglobulin tests (DAT)
    • Patients with warm autoantibodies
    • Patients with sickle cell disease or thalassemia
    • Patients who have been transfused and developed an antibody
    • Patients needing long-term transfusion support
    • Patients whose RBCs demonstrate spontaneous agglutination
  • Resolution of complex antibody identification and/or distinguish allo from autoantibody
  • Resolution of ABO or Rh typing discrepancies
  • Confirmation of weak or partial D phenotypes in women of childbearing age to guide transfusion and/or RhIG administration
  • Identification of antigen-negative donor units if antisera is unavailable or limited in supply
  • Typing of panel cells for uncommon or weakly expressed antigens
  • Identification of novel antigens or phenotypes
  • Testing for platelet antigens and post-transfusion purpura (PTP) 

Fetal or Neonatal Testing

  • Evaluation of fetal risk for hemolytic disease of the fetus or newborn (HDFN) due to maternal antibodies to red cell antigens
  • Evaluation of fetal risk for alloimmune thrombocytopenia (NAIT) due to maternal antibodies to platelet antigens
  • Confirmation of maternal type, paternal zygosity, and fetal type 

Platelet Antigen Typing

Genomic DNA testing can improve platelet typing accuracy, help select compatible donors, aid the management and treatment for platelet destruction, and improve transfusion safety and outcomes for patients.

Indications

  • Testing for platelet antigens and post-transfusion purpura (PTP)
  • Evaluation of fetal risk for alloimmune thrombocytopenia (NAIT) due to maternal antibodies to platelet antigens including:
    • Determining maternal and paternal HPA type 
    • Typing of fetal amniocytes or chorionic villus sample (CVS) 

Typing for the following platelet antigens is available:

  • HPA-1a/1b (PLA)
  • HPA- 2a/2b (Ko)
  • HPA-3a/3b (Bak)
  • HPA -4a/4b (Pen)
  • HPA-5a/5b (Br)
  • HPA-15a/15b (Gov)
  • HPA Array Panel: includes HPA 1 through 9, 11, and 15

Platelet Antibody Screening and Platelet Cross Match

NYBC offers platelet antibody screening and platelet cross matching to supply compatible single donor platelet pheresis to the patient who has become refractory to random donor platelets and platelet pheresis products. Immune destruction of platelets can occur in patients with selected hematologic disorders (leukemia, systemic lupus erythematosis, and other collagen-vascular diseases). In vitro antibody screening tests detect the presence of these antibodies in patient (or donor) sera.

Want more information?

718.752.4637
molecular@nybloodcenter.org

Forms

Request for Serological Investigation Form

Request for DNA Analysis of Blood Groups Form

Helpful Resources

Facts & Information for RhD Genotyping